HK1206344A1 - 作為 抑制劑的二氟-六氫-環戊二烯並噁嗪基類和二氟-六氫-苯並噁嗪基類 - Google Patents

作為 抑制劑的二氟-六氫-環戊二烯並噁嗪基類和二氟-六氫-苯並噁嗪基類

Info

Publication number
HK1206344A1
HK1206344A1 HK15106931.2A HK15106931A HK1206344A1 HK 1206344 A1 HK1206344 A1 HK 1206344A1 HK 15106931 A HK15106931 A HK 15106931A HK 1206344 A1 HK1206344 A1 HK 1206344A1
Authority
HK
Hong Kong
Prior art keywords
bace1
ang
vegf
antibodies
treatment
Prior art date
Application number
HK15106931.2A
Other languages
English (en)
Inventor
漢斯.希爾珀特
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1206344A1 publication Critical patent/HK1206344A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
HK15106931.2A 2012-06-26 2015-07-21 作為 抑制劑的二氟-六氫-環戊二烯並噁嗪基類和二氟-六氫-苯並噁嗪基類 HK1206344A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12173690 2012-06-26
PCT/EP2013/063086 WO2014001228A1 (en) 2012-06-26 2013-06-24 Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors

Publications (1)

Publication Number Publication Date
HK1206344A1 true HK1206344A1 (zh) 2016-01-08

Family

ID=48672630

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106931.2A HK1206344A1 (zh) 2012-06-26 2015-07-21 作為 抑制劑的二氟-六氫-環戊二烯並噁嗪基類和二氟-六氫-苯並噁嗪基類

Country Status (22)

Country Link
US (1) US9181232B2 (zh)
EP (1) EP2864324B1 (zh)
JP (1) JP6251257B2 (zh)
KR (1) KR20150023450A (zh)
CN (1) CN104470915B (zh)
AU (1) AU2013283524B2 (zh)
BR (1) BR112014029742A2 (zh)
CA (1) CA2872181A1 (zh)
CL (1) CL2014003325A1 (zh)
CO (1) CO7151509A2 (zh)
CR (1) CR20140528A (zh)
EA (1) EA025273B1 (zh)
HK (1) HK1206344A1 (zh)
IL (1) IL236138A (zh)
MA (1) MA37763B1 (zh)
MX (1) MX2014014937A (zh)
NZ (1) NZ702253A (zh)
PE (1) PE20142450A1 (zh)
PH (1) PH12014502623B1 (zh)
SG (1) SG11201407576YA (zh)
UA (1) UA113309C2 (zh)
WO (1) WO2014001228A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102119161B (zh) 2008-06-13 2015-07-08 盐野义制药株式会社 具有β分泌酶抑制作用的含硫杂环衍生物
JPWO2011071135A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
MX366855B (es) 2013-03-01 2019-07-26 Amgen Inc Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso.
MX2015011618A (es) 2013-03-08 2015-12-17 Amgen Inc Compuestos de 1,3-oxazin-2-amina fusionados con ciclopropilo perfluorado como inhibidores de beta-secretasa y metodos de uso.
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有bace1抑制活性之二氫噻及二氫衍生物
MX2017001794A (es) 2014-08-08 2017-06-29 Amgen Inc Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
US10047081B2 (en) 2015-03-20 2018-08-14 Hoffman-La Roche Inc. BACE1 inhibitors
TW202014191A (zh) 2018-04-27 2020-04-16 日商鹽野義製藥股份有限公司 具有選擇性bace1抑制活性的四氫哌喃并衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
GB0912778D0 (en) * 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UA103272C2 (uk) * 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
JPWO2011071135A1 (ja) * 2009-12-11 2013-04-22 塩野義製薬株式会社 オキサジン誘導体

Also Published As

Publication number Publication date
CA2872181A1 (en) 2014-01-03
CN104470915A (zh) 2015-03-25
UA113309C2 (xx) 2017-01-10
MA37763B1 (fr) 2017-05-31
EA201590066A1 (ru) 2015-04-30
CR20140528A (es) 2015-01-12
CL2014003325A1 (es) 2015-04-24
JP6251257B2 (ja) 2017-12-20
PH12014502623A1 (en) 2015-01-21
KR20150023450A (ko) 2015-03-05
IL236138A0 (en) 2015-02-01
CO7151509A2 (es) 2014-12-29
EP2864324A1 (en) 2015-04-29
PE20142450A1 (es) 2015-01-28
PH12014502623B1 (en) 2015-01-21
EP2864324B1 (en) 2018-03-28
SG11201407576YA (en) 2015-03-30
AU2013283524B2 (en) 2017-03-30
EA025273B1 (ru) 2016-12-30
NZ702253A (en) 2016-06-24
CN104470915B (zh) 2019-07-26
MA37763A1 (fr) 2016-08-31
IL236138A (en) 2016-10-31
WO2014001228A1 (en) 2014-01-03
JP2015521640A (ja) 2015-07-30
MX2014014937A (es) 2015-03-09
AU2013283524A1 (en) 2014-11-13
US20150133440A1 (en) 2015-05-14
US9181232B2 (en) 2015-11-10
BR112014029742A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
HUS2300008I1 (hu) Bispecifikus anti-VEGF/anti-ANG-2 antitestek és ezek alkalmazása szemészeti érbetegségek kezelésében
HK1206344A1 (zh) 作為 抑制劑的二氟-六氫-環戊二烯並噁嗪基類和二氟-六氫-苯並噁嗪基類
HK1213192A1 (zh) 用於在人類受試者中治療眼部疾病的方法和裝置
HK1246646A1 (zh) 用於治療糖尿病性視網膜病及其他眼科疾病的方法
EP2890440A4 (en) DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
HK1215868A1 (zh) 雙特異性構建體及其用於治療多種疾病的用途
IL274398A (en) ANTI-IGF-1R antibodies that eliminate binding to FCRN and their use in the treatment of vascular diseases of the eye
HK1211960A1 (zh) 治療血管疾病及其併發症
IL239078A0 (en) Protein for use in the treatment of eye diseases
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230623